This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
PRTK 주식 개요
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
보상
위험 분석
Paratek Pharmaceuticals, Inc. 경쟁사
가격 내역 및 성능
| 과거 주가 | |
|---|---|
| 현재 주가 | US$2.23 |
| 52주 최고치 | US$3.65 |
| 52주 최저치 | US$1.29 |
| 베타 | 1.7 |
| 11개월 변경 | 2.29% |
| 3개월 변경 사항 | 0.91% |
| 1년 변경 사항 | -2.62% |
| 33년 변화 | -60.95% |
| 5년 변화 | -77.01% |
| IPO 이후 변화 | -86.06% |
최근 뉴스 및 업데이트
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06주주 수익률
| PRTK | US Pharmaceuticals | US 마켓 | |
|---|---|---|---|
| 7D | 2.3% | -1.7% | 0.8% |
| 1Y | -2.6% | 21.6% | 33.4% |
수익률 대 산업: PRTK underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
수익률 대 시장: PRTK underperformed the US Market which returned 13.8% over the past year.
가격 변동성
| PRTK volatility | |
|---|---|
| PRTK Average Weekly Movement | 1.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: PRTK has not had significant price volatility in the past 3 months.
시간에 따른 변동성: PRTK's weekly volatility has decreased from 13% to 2% over the past year.
회사 소개
| 설립 | 직원 | CEO | 웹사이트 |
|---|---|---|---|
| 1996 | 269 | Evan Loh | www.paratekpharma.com |
Paratek Pharmaceuticals, Inc. 기본 사항 요약
| PRTK 기본 통계 | |
|---|---|
| 시가총액 | US$127.83m |
| 수익(TTM) | -US$62.73m |
| 수익(TTM) | US$177.00m |
0.7x
P/S 비율-2.0x
P/E 비율PRTK 주가가 과대평가되어 있나요?
공정 가치 및 가치 분석 보기수익 및 수익
| PRTK 손익 계산서(TTM) | |
|---|---|
| 수익 | US$177.00m |
| 수익 비용 | US$64.13m |
| 총 이익 | US$112.87m |
| 기타 비용 | US$175.60m |
| 수익 | -US$62.73m |
최근 보고된 수익
Jun 30, 2023
다음 수익 날짜
n/a
| 주당 순이익(EPS) | -1.09 |
| 총 마진 | 63.77% |
| 순이익 마진 | -35.44% |
| 부채/자본 비율 | -128.3% |
PRTK 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기